Background Few medical studies have clarified the prognostic factors that affect

Background Few medical studies have clarified the prognostic factors that affect medical outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after immunochemotherapy. International Prognostic Index (aa-IPI). Risk assessment according to SUVmax at relapse The median SUVmax was 10.9 (range, 2.9-33.0). The ideal cut-off for SUVmax was 6.0 according to ROC curve analysis. The area under the ROC curve of SUVmax was 0.811. The level of sensitivity and specificity were 90.1 and 73.1%, respectively. Depending on his or her SUVmax, each patient was classified into either the low (<6.0) or high SUVmax group (6.0). Relating to this cut-off value, significant variations in survival were observed (<0.001 for PFS and <0.001 for OS, Fig. 2A-B). Fig. 2 Assessment of medical outcomes according to a maximum standardized uptake value (SUVmax) cut-off of 6.0. Prognostic factors affecting medical outcomes To examine whether medical outcomes were affected by various prognostic factors (age65 years, low aa-IPI, SUVmax <6.0, time-to-relapse >12 weeks, and CR Telmisartan status after salvage therapy), the factors were analyzed regarding their prognostic significance for salvage therapy. In univariate analysis, a low aa-IPI (<0.001 for PFS, <0.001 for OS), SUVmax <6.0 (<0.001 for PFS, <0.001 for OS), time to relapse >12 months (=0.025 for PFS, <0.001 for OS), and CR status after the therapy (=0.002 for PFS, <0.001 for OS) were associated with both PFS and OS (Table 2). Table 2 Univariate analysis of the prognostic factors predicting the Telmisartan medical outcomes. Multivariate analysis revealed that a low aa-IPI (<0.001 for PFS, <0.001 for OS), SUVmax <6.0 (<0.001 for PFS, <0.001 for OS), and time to relapse 12 months (<0.057 for PFS, <0.001 for OS) were indie prognostic factors associated with favorable outcomes (Table 3). Table 3 Multivariate analysis of the prognostic factors predicting the medical outcomes. Conversation Few studies have been devoted to restorative options for individuals with relapsed DLBCL who are ineligible for HDT/ASCT. It is well known the prognosis is extremely poor with few restorative options. The best restorative treatment is definitely palliative chemotherapy together with additional interventions to preserve a high quality of existence. However, some subgroups of relapsed individuals with low risk accomplish a second good response and encounter long term survival. Therefore, it is important to identify prognostic factors for predicting long-term results in this populace. Several studies suggested the medical value of particular prognostic factors including a tumor mass Telmisartan dimensions larger than 10 cm, restorative regimens prior to ASCT, elevated LDH levels, short time to relapse, and an overall high disease burden [9,10,11,12,13,14]. However, the widely approved solitary prognostic model in the relapsed/refractory establishing could not become generalized. A recent study illustrated the prognostic significance of aa-IPI based on the medical data of individuals with relapsed NHL who underwent HDT/ASCT [15,16,17]. Guglielmi et al. also performed a retrospective analysis of aa-IPI factors for individuals with relapsed DLBCL and recognized relapse within 12 months of the initial analysis and aa-IPI factors as significant self-employed prognostic factors [18]. In addition, other medical studies shown the positive predictive value of aa-IPI [3,19,20]. However, Telmisartan these results cannot be generalized to all individuals with NHL because the aa-IPI factors were mostly focused on individuals who underwent HDT/ASCT. Conversely, Rabbit Polyclonal to EGFR (phospho-Ser1026) the present study was designed to evaluate the prognostic value of aa-IPI for individuals with relapsed or refractory DLBCL who were ineligible for HDT/ASCT, and the data suggested that a low aa-IPI is definitely associated with beneficial results for HDT/ASCT-ineligible individuals. Several research organizations have investigated the use of 18F-FDG PET/CT to predict the outcomes of.

Comments are closed.